Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fatty acid intake linked to colon cancer risk in new study

NCT ID NCT01966081

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating certain fats (polyunsaturated fatty acids) is linked to colorectal cancer risk. Researchers measured fatty acids in fat tissue and blood samples from 551 people with and without colorectal cancer. The goal was to find reliable biomarkers that could help understand diet's role in cancer risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

551 people

The number who actually took part.

Started

Sep 2008

Finished

Jun 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: CASES * Patients aged ≥ 45 years * with a first recently-diagnosed colorectal cancer * due to undergo elective surgical resection with curative intent (in practice, stage I, II, III or IV if there was only one hepatic nodule that was resected with curative intent) in one of the 5 following digestive surgery units: CHU de Dijon, CHU de Nancy, CHU de Strasbourg, CHU de Reims et CHU and Besançon. * who have given their informed consent CONTROLS * Patients aged ≥ 45 years * due to undergo surgery for a benign abdominal disease (sigmoid diverticulitis, appendectomy, hiatal hernia …) * matched for abdominal site with cases for age (± 3 years), sex and hospital * Who have given their informed consent Exclusion Criteria: CASES * pre-operative anticancer treatment (chemo or radiotherapy) * existence of visceral metastases except a single hepatic nodule resected with curative intent * familial adenomatous polyposis and HNPCC syndrome (when suspected: inclusion after complementary tumor phenotype study: screening for microsatellite instability and/or immunohistochemistry study of the expression of DNA mismatch repair proteins. * known inflammatory disease of the intestine (ulcerative colitis, Crohn's disease) * personal history (recent or not) of colorectal cancer * emergency treatment for the presenting complication (perforation, occlusion…) * significant modification in dietary habits during the previous three months * other evolving neoplastic disease * psychic state incompatible with understanding the modalities and the aims of the study (notably patients under guardianship) * pregnant or breast-feeding women CONTROLS * personal history of cancer or adenomatous colorectal polyps, * emergency intervention * known inflammatory disease of the intestine (ulcerative colitis, Crohn's disease) * personal history (recent or not) of colorectal cancer * emergency treatment for the presenting complication (perforation, occlusion…) * significant modification in dietary habits during the previous three months * evolving neoplastic disease * psychic state incompatible with understanding the modalities and the aims of the study (notably patients under guardianship) * pregnant or breast-feeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for First recently-diagnosed colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Dijon

    Dijon, 21079, France

  • CHU Jean Minjoz

    Besançon, 25030, France

  • Hôpital Hautepierre

    Strasbourg, 67200, France

  • Hôpital Robert Debré

    Reims, 51092, France

  • Hôpital de BRABOIS

    Vandœuvre-lès-Nancy, 54511, France